Journal of cataract and refractive surgery · 2012
Accelerated corneal crosslinking concurrent with laser in situ keratomileusis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Celik H Ugur, Alagöz Nese, Yildirim Yusuf, Agca Alper, Marshall John, Demirok Ahmet, Yilmaz Omer Faruk
Аннотация
PURPOSE: To assess accelerated corneal collagen crosslinking (CXL) applied concurrently with laser in situ keratomileusis (LASIK) in a small group of patients.
SETTING: Beyoglu Eye Research and Training Hospital, Istanbul, Turkey.
DESIGN: Prospective pilot interventional case series.
METHODS: In May 2010, patients had LASIK with concurrent accelerated CXL in 1 eye and LASIK only in the fellow eye to treat myopia or myopic astigmatism. The follow-up was 12 months. The attempted correction (spherical equivalent) ranged from -5.00 to -8.50 diopters (D) in the LASIK-CXL group and from -3.00 to -7.25 D in the LASIK-only group. Main outcome measures were manifest refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, and the endothelial cell count.
RESULTS: Eight eyes of 3 women and 1 man (age 22 to 39 years old) were enrolled. At the 12-month follow-up, the LASIK-CXL group had a UDVA and manifest refraction equal to or better than those in the LASIK-only group. No eye lost 1 or more lines of CDVA at the final visit. The endothelial cell loss in the LASIK-CXL eye was not greater than in the fellow eye. No side effects were associated with either procedure.
CONCLUSIONS: Laser in situ keratomileusis with accelerated CXL appears to be a promising modality for future applications to prevent corneal ectasia after LASIK treatment. The results in this pilot series suggest that evaluation of a larger study cohort is warranted.
FINANCIAL DISCLOSURE: Drs. Yilmaz and Marshall are paid consultants to Avedro, Inc. No other author has a financial or proprietary interest in any material or method mentioned.
SETTING: Beyoglu Eye Research and Training Hospital, Istanbul, Turkey.
DESIGN: Prospective pilot interventional case series.
METHODS: In May 2010, patients had LASIK with concurrent accelerated CXL in 1 eye and LASIK only in the fellow eye to treat myopia or myopic astigmatism. The follow-up was 12 months. The attempted correction (spherical equivalent) ranged from -5.00 to -8.50 diopters (D) in the LASIK-CXL group and from -3.00 to -7.25 D in the LASIK-only group. Main outcome measures were manifest refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, and the endothelial cell count.
RESULTS: Eight eyes of 3 women and 1 man (age 22 to 39 years old) were enrolled. At the 12-month follow-up, the LASIK-CXL group had a UDVA and manifest refraction equal to or better than those in the LASIK-only group. No eye lost 1 or more lines of CDVA at the final visit. The endothelial cell loss in the LASIK-CXL eye was not greater than in the fellow eye. No side effects were associated with either procedure.
CONCLUSIONS: Laser in situ keratomileusis with accelerated CXL appears to be a promising modality for future applications to prevent corneal ectasia after LASIK treatment. The results in this pilot series suggest that evaluation of a larger study cohort is warranted.
FINANCIAL DISCLOSURE: Drs. Yilmaz and Marshall are paid consultants to Avedro, Inc. No other author has a financial or proprietary interest in any material or method mentioned.
Предметные рубрики MeSH
AdultAstigmatismCell CountCollagenCombined Modality TherapyCorneal StromaCross-Linking ReagentsDilatation, PathologicEndothelium, CornealFemaleHumansKeratomileusis, Laser In SituLasers, ExcimerMaleMyopiaPhotochemotherapyPhotosensitizing AgentsPilot ProjectsPostoperative ComplicationsProspective StudiesRefraction, OcularRiboflavinTreatment OutcomeUltraviolet RaysVisual AcuityYoung Adult